Pardes Biosciences
Carlsbad · Founded 2020
About Pardes Biosciences
Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $126.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2021)
- Ticker: nasdaq:PRDS
- Website: https://www.pardesbio.com
- Phone: 415-649-8758
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/pardes-biosciences-455 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.